GlassScriptPhysician profile
Norman A Floro
NPI 1124042387
$3,953.20
in general payments reported to CMS, 2019-2025
29 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $139 · 2021: $591 · 2022: $353 · 2023: $790 · 2024: $745 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,395.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.02 | 2023-2025 | |
| Novo Nordisk INC | $587.32 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $541.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $524.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $262.92 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $201.54 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $187.10 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.77 | 2021-2024 | |
| Amgen INC. | $124.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $123.95 | 2021 | |
| Abbott Laboratories | $122.61 | 2021-2025 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $67.24 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $53.06 | 2021 | |
| Xeris Pharmaceuticals, INC. | $41.00 | 2023-2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $40.96 | 2022-2023 | Vyvanse |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.81 | 2021-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.85 | 2025 | Caplyta |
| Currax Pharmaceuticals LLC | $34.01 | 2023-2024 | Contrave |
| Dexcom, INC. | $32.23 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $28.08 | 2021-2022 | |
| Astellas Pharma US INC | $20.54 | 2025 | Veozah |
| Tonix Medicines, INC. | $20.49 | 2025 | Tonmya |
| Inspire Medical Systems, INC. | $19.02 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $18.30 | 2022 | |
| Oyster Point Pharma, INC. | $18.24 | 2023 | Tyrvaya |
| Exact Sciences Corporation | $16.56 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.37 | 2024 | Jardiance |
| Axsome Therapeutics, INC. | $13.28 | 2024 | Auvelity |
| Esperion Therapeutics, INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Floro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.